{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T03:41:47Z","timestamp":1782272507275,"version":"3.54.5"},"reference-count":176,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>As one of a series of thematically linked reviews of the primary pharmacology of the \u03b2-lactam\/\u03b2-lactamase inhibitor combination, ceftazidime\/avibactam, this article reviews the microbiological findings in drug-exposed patients. Earlier articles in the series focused on basic in vitro and in vivo translational biology (J Antimicrob Chemother 2022; 77: 2321\u201340 and 2341\u201352) and the development and mechanisms of resistance in vitro (J Antimicrob Chemother 2023: Epub ahead of print. doi: 10.1093\/jac\/dkac449). In clinical trials of ceftazidime\/avibactam, combined favourable microbiological responses for evaluable patients infected at baseline by susceptible Enterobacterales or Pseudomonas aeruginosa were 86.1% (851\/988). The corresponding percent favourable among patients infected by ceftazidime\/avibactam-resistant pathogens was 58.8% (10\/17), noting that the majority (15\/17) of the resistant examples were P. aeruginosa. Microbiological response rates to comparator treatments in the same clinical trials ranged between 64% and 95%, depending on the type of infection and the analysis population. Uncontrolled case studies over a wide range of patients infected by antibiotic multiresistant Gram-negative bacteria have demonstrated that ceftazidime\/avibactam can elicit microbiological clearance of ceftazidime\/avibactam-susceptible strains. In case studies where a matched cohort of patients had been treated with antibacterial agents other than ceftazidime\/avibactam, microbiological outcomes were comparable between treatments, mostly being observationally more favourable for ceftazidime\/avibactam (recognizing that numbers were too small for definitive superiority assessments). Development of resistance to ceftazidime\/avibactam during therapy is reviewed. The phenomenon has been reported multiple times, mostly in difficult-to-treat patients infected by KPC-producing Enterobacterales. Molecular mechanisms, when determined, have frequently been observed previously in vitro, such as the \u2018\u03a9-loop\u2019 D179Y (Asp179Tyr) substitution found in KPC variant enzymes. In human volunteers exposed to therapeutic levels of ceftazidime\/avibactam, faecal numbers of Escherichia coli, other enterobacteria, lactobacilli, bifidobacteria, clostridia and Bacteroides spp. decreased. Clostridioides difficile was detected in the faeces, but this was of uncertain significance, because no unexposed controls were studied.<\/jats:p>","DOI":"10.1093\/jac\/dkad049","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T12:27:40Z","timestamp":1678278460000},"page":"871-892","source":"Crossref","is-referenced-by-count":12,"title":["The primary pharmacology of ceftazidime\/avibactam: microbiology from clinical studies, and development of resistance during treatment"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3305-6388","authenticated-orcid":false,"given":"Wright W","family":"Nichols","sequence":"first","affiliation":[{"name":"Microbiology Consulting, The Stables, 2\u20134 Davenfield Road, Didsbury , M20 6UP, Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1285-2978","authenticated-orcid":false,"given":"Patricia A","family":"Bradford","sequence":"additional","affiliation":[{"name":"Antimicrobial Development Specialists, LLC, Nyack, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory G","family":"Stone","sequence":"additional","affiliation":[{"name":"Hospital Business Unit, Global Product Development, Pfizer , Groton, CT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.mib.2011.07.026","article-title":"Diazabicyclooctanes (DBOs): a potent new class of non-\u03b2-lactam \u03b2-lactamase inhibitors","volume":"14","author":"Coleman","year":"2011","journal-title":"Curr Op Microbiol"},{"key":"2023040308031609500_","author":"EMA.","year":"2022"},{"key":"2023040308031609500_","author":"FDA.","year":"2019"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1093\/jac\/dkac171","article-title":"The primary pharmacology of ceftazidime\/avibactam: in vitro translational biology","volume":"77","author":"Nichols","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/jac\/dkac172","article-title":"The primary pharmacology of ceftazidime\/avibactam: in vivo translational biology and pharmacokinetics\/pharmacodynamics (PK\/PD)","volume":"77","author":"Nichols","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/jac\/dkac449","article-title":"The primary pharmacology of ceftazidime\/avibactam: resistance in vitro","volume":"78","author":"Nichols","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"ofz149","DOI":"10.1093\/ofid\/ofz149","article-title":"Randomized trial of ceftazidime-avibactam vs meropenem for treatment of hospital-acquired and ventilator-associated bacterial pneumonia (REPROVE): analyses per US FDA\u2013specified end points","volume":"6","author":"Torres","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"341ps12","DOI":"10.1126\/scitranslmed.aaf5027","article-title":"What does research reproducibility mean?","volume":"8","author":"Goodman","year":"2016","journal-title":"Sci Transl Med"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40265-018-0902-x","article-title":"Ceftazidime-avibactam: a review in the treatment of serious Gram-negative bacterial infections","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1093\/jac\/dky124","article-title":"Efficacy and safety of ceftazidime\/avibactam: a systematic review and meta-analysis","volume":"73","author":"Sternbach","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2217\/fmb-2020-0012","article-title":"Update on the role of ceftazidime-avibactam in the management of carbapenemase-producing Enterobacterales","volume":"15","author":"Dietl","year":"2020","journal-title":"Future Microbiol"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jgar.2021.04.001","article-title":"Resistance to ceftazidime\/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies","volume":"25","author":"Di Bella","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s40121-021-00507-6","article-title":"Ceftazidime-avibactam for the treatment of serious Gram-negative infections with limited treatment options: a systematic literature review","volume":"10","author":"Soriano","year":"2021","journal-title":"Infect Dis Ther"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.3390\/antibiotics10091126","article-title":"Review of ceftazidime-avibactam for the treatment of infections caused by Pseudomonas aeruginosa","volume":"10","author":"Daikos","year":"2021","journal-title":"Antibiotics"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s15010-022-01876-x","article-title":"Update of clinical application in ceftazidime\u2013avibactam for multidrug-resistant Gram-negative bacteria infections","volume":"50","author":"Zhen","journal-title":"Infection"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3390\/antibiotics11050579","article-title":"New drugs for the treatment of Pseudomonas aeruginosa infections with limited treatment options: a narrative review","volume":"11","author":"Losito","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"6137","DOI":"10.1128\/AAC.00851-12","article-title":"Comparative in vitro and in vivo efficacy of human simulated exposures of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa","volume":"56","author":"Crandon","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1128\/AAC.02161-13","article-title":"Efficacy of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model","volume":"58","author":"Housman","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"6913","DOI":"10.1128\/AAC.03267-14","article-title":"In vivo efficacy of humanized exposures of ceftazidime-avibactam in comparison with ceftazidime against contemporary Enterobacteriaceae isolates","volume":"58","author":"MacVane","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/cid\/cix246","article-title":"Progress in the fight against multidrug-resistant bacteria 2005\u20132016: modern noninferiority trial designs enable antibiotic development in advance of epidemic bacterial resistance","volume":"65","author":"Rex","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1128\/AAC.01173-15","article-title":"\u03b2-Lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the phase 2 trials for ceftazidime-avibactam: clinical efficacies analyzed against subsets of molecularly characterized isolates","volume":"60","author":"Mendes","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial","volume":"68","author":"Lucasti","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","article-title":"Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study","volume":"28","author":"Vazquez","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/INF.0000000000002392","article-title":"Safety and efficacy of ceftazidime-avibactam plus metronidazole in the treatment of children \u22653 months to &lt;18 years with complicated intra-abdominal infection: results from a phase 2, randomized, controlled trial","volume":"38","author":"Bradley","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/INF.0000000000002395","article-title":"Safety and efficacy of ceftazidime-avibactam in the treatment of children \u22653 months to &lt;18 years with complicated urinary tract infection: results from a phase 2 randomized, controlled trial","volume":"38","author":"Bradley","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"2023040308031609500_","first-page":"1396","article-title":"In vitro activity of ceftazidime\/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infection","volume":"72","author":"Stone","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e02447-16","DOI":"10.1128\/AAC.02447-16","article-title":"Molecular \u03b2-lactamase characterization of aerobic Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials for complicated intra-abdominal infections, with efficacies analyzed against susceptible and resistant subsets","volume":"61","author":"Mendes","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e02584-17","DOI":"10.1128\/AAC.02584-17","article-title":"In vitro activity of ceftazidime-avibactam against isolates from patients in a phase 3 clinical trial for treatment of complicated intra-abdominal infections","volume":"62","author":"Stone","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","article-title":"A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia","volume":"49","author":"Qin","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e02356-19","DOI":"10.1128\/AAC.02356-19","article-title":"In vitro activity of ceftazidime-avibactam against isolates from respiratory and blood specimens from patients with nosocomial pneumonia, including ventilator-associated pneumonia, in a phase 3 clinical trial","volume":"64","author":"Stone","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e02655-18","DOI":"10.1128\/AAC.02655-18","article-title":"Characterization of \u03b2-lactamase content of ceftazidime-resistant pathogens recovered during the pathogen-directed phase 3 REPRISE trial for ceftazidime-avibactam: correlation of efficacy against \u03b2-lactamase producers","volume":"63","author":"Mendes","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e01820-16","DOI":"10.1128\/AAC.01820-16","article-title":"In vitro activity of ceftazidime-avibactam against isolates in a phase 3 open-label clinical trial for complicated intra-abdominal and urinary tract infections caused by ceftazidime-nonsusceptible Gram-negative pathogens","volume":"61","author":"Stone","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S1473-3099(16)30265-1","article-title":"Ceftazidime-avibactam in ceftazidime-resistant infections","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(16)30025-1","article-title":"Studying ceftazidime-avibactam in selected populations","volume":"16","author":"Wagenlehner","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1093\/jac\/dky204","article-title":"Clinical activity of ceftazidime\/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime\/avibactam Phase III clinical trial programme","volume":"73","author":"Stone","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e0198521","DOI":"10.1128\/aac.01985-21","article-title":"Antimicrobial activity of ceftazidime-avibactam and comparators against pathogens harboring OXA-48 and AmpC alone or in combination with other \u03b2-lactamases collected from phase 3 clinical trials and an international surveillance program","volume":"66","author":"Lin","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1146\/annurev.mi.41.100187.003041","article-title":"Chromosomal cephalosporinases responsible for multiple resistance to newer \u03b2-lactam antibiotics","volume":"41","author":"Sanders","year":"1987","journal-title":"Annu Rev Microbiol"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.1128\/AAC.03057-14","article-title":"Avibactam and class C \u03b2-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance","volume":"58","author":"Lahiri","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"5575","DOI":"10.1099\/ijsem.0.001485","article-title":"Genome-based phylogeny and taxonomy of the \u2018Enterobacteriales\u2019: proposal for Enterobacterales ord. nov. divided into the families Enterobacteriaceae, Erwiniaceae fam. nov., Pectobacteriaceae fam. nov., Yersiniaceae fam. nov., Hafniaceae fam. nov., Morganellaceae fam. nov., and Budviciaceae fam. nov","volume":"66","author":"Adeolu","year":"2016","journal-title":"Int J Syst Evol Microbiol"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1128\/AAC.03042-15","article-title":"In vitro susceptibility to ceftazidime-avibactam of carbapenem non-susceptible Enterobacteriaceae collected in the INFORM global surveillance study (2012\u20132014)","volume":"60","author":"De Jonge","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e02569-17","DOI":"10.1128\/AAC.02569-17","article-title":"In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Asia-Pacific countries: results from the INFORM global surveillance program, 2012 to 2015","volume":"62","author":"Karlowsky","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e01814-18","DOI":"10.1128\/AAC.01814-18","article-title":"In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Latin American countries: results from the INFORM global surveillance program, 2012 to 2015","volume":"63","author":"Karlowsky","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1128\/AAC.00220-16","article-title":"In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime-avibactam: INFORM 2012\u20132014","volume":"60","author":"Nichols","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijantimicag.2016.01.004","article-title":"In vitro activity of ceftazidime\/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients","volume":"47","author":"Flamm","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00228-019-02804-z","article-title":"Selecting the dosage of ceftazidime-avibactam in the perfect storm of nosocomial pneumonia","volume":"76","author":"Das","year":"2020","journal-title":"Eur J Clin Pharm"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e02313-19","DOI":"10.1128\/AAC.02313-19","article-title":"Meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae infections","volume":"64","author":"Ackley","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1186\/s12879-019-4409-1","article-title":"Efficacy of ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"19","author":"Alraddadi","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e01551-18","DOI":"10.1128\/AAC.01551-18","article-title":"Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-resistant Klebsiella pneumoniae bacteremia and abscess in a liver transplant recipient","volume":"63","author":"Athans","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","first-page":"9028543","article-title":"Successful treatment of Klebsiella pneumoniae harboring a Klebsiella pneumoniae carbapenemase isolated from lumbar wound infection and blood in a patient with hardware retention","author":"Bulbin","year":"2017","journal-title":"Case Rep Infect Dis"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0167-4781(94)90011-6","article-title":"Sequence analysis of the L1 metallo-\u03b2-lactamase from Xanthomonas maltophilia","volume":"1218","author":"Walsh","year":"1994","journal-title":"Biochim Biophys Acta"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3390\/antibiotics11081007","article-title":"Ceftazidime\/avibactam in ventilator-associated pneumonia due to difficult-to-treat non-fermenter Gram-negative bacteria in COVID-19 patients: a case series and review of the literature","volume":"11","author":"Burastero","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1128\/AAC.00655-15","article-title":"Successful treatment of carbapenemase-producing pandrug-resistant Klebsiella pneumoniae bacteremia","volume":"59","author":"Camargo","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijid.2017.03.021","article-title":"Clinical efficacy of ceftazidime\/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients","volume":"59","author":"Cast\u00f3n","year":"2017","journal-title":"Int J Infect Dis"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"106075","DOI":"10.1016\/j.ijantimicag.2020.106075","article-title":"Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort","volume":"56","author":"Cast\u00f3n","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/jac\/dkac049","article-title":"Impact of ceftazidime\/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study)","volume":"77","author":"Cast\u00f3n","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1093\/jac\/dkaa241","article-title":"Phenotypic and genotypic analysis of KPC-51 and KPC-52, two novel KPC-2 variants conferring resistance to ceftazidime\/avibactam in the KPC-producing Klebsiella pneumoniae ST11 clone background","volume":"75","author":"Sun","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"39","DOI":"10.21037\/atm.2019.10.40","article-title":"Clinical outcomes of ceftazidime-avibactam in lung transplant recipients with infections caused by extensively drug-resistant gram-negative bacilli","volume":"8","author":"Chen","year":"2020","journal-title":"Ann Transl Med"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2147\/IDR.S350976","article-title":"Ceftazidime\/avibactam versus polymyxin B in the challenge of carbapenem-resistant Pseudomonas aeruginosa infection","volume":"15","author":"Chen","year":"2022","journal-title":"Infect Drug Res"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"106517","DOI":"10.1016\/j.ijantimicag.2021.106517","article-title":"Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa","volume":"59","author":"Corbella","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3390\/antibiotics9100640","article-title":"Ceftolozane\/tazobactam and ceftazidime\/avibactam for multidrug-resistant Gram-negative infections in immunocompetent patients: a single-center retrospective study","volume":"9","author":"Cultrera","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ijantimicag.2018.11.015","article-title":"Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam","volume":"53","author":"de la Calle","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jgar.2021.04.022","article-title":"Ceftazidime-avibactam in the treatment of infections from carbapenem-resistant Klebsiella pneumoniae: ceftazidime-avibactam against CR-KP infections","volume":"26","author":"Gu","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e7664","DOI":"10.1097\/MD.0000000000007664","article-title":"Successful ceftazidime-avibactam treatment of MDR-KPC-positive Klebsiella pneumoniae infection in a patient with traumatic brain injury. A case report","volume":"96","author":"Gugliandolo","year":"2017","journal-title":"Medicine"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/jac\/dkx358","article-title":"Ceftazidime\/avibactam use for carbapenem-resistant Klebsiella pneumoniae meningitis: a case report","volume":"73","author":"Holyk","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s15010-018-1166-9","article-title":"A challenging case of carbapenemase-producing Klebsiella pneumoniae septic thrombophlebitis and right mural endocarditis successfully treated with ceftazidime\/avibactam","volume":"46","author":"Iacovelli","year":"2018","journal-title":"Infection"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/1120009X.2019.1709363","article-title":"Ceftazidime-avibactam susceptible to resistant KPC-producing Enterobacterales bloodstream infections: an observational study","volume":"32","author":"Iannaccone","year":"2020","journal-title":"J Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ijantimicag.2016.06.002","article-title":"Combination treatment with extended-infusion ceftazidime\/avibactam for a KPC-3-producing Klebsiella pneumoniae bacteraemia in a kidney and pancreas transplant patient","volume":"48","author":"Jacobs","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"ofz522","DOI":"10.1093\/ofid\/ofz522","article-title":"Real-world experience with ceftazidime-avibactam for multidrug-resistant Gram-negative bacterial infections","volume":"6","author":"Jorgensen","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1093\/jac\/dkx179","article-title":"Emergence of ceftazidime\/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate","volume":"72","author":"Both","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e0195757","DOI":"10.1371\/journal.pone.0195757","article-title":"Carbapenem-resistant Gram-negative pathogens in a German university medical center: prevalence, clinical implications and the role of novel \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"13","author":"Katchanov","year":"2018","journal-title":"PLoS One"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e00449-17","DOI":"10.1128\/AAC.00449-17","article-title":"Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae infections","volume":"61","author":"King","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.ijantimicag.2017.01.018","article-title":"Treating complicated carbapenem-resistant Enterobacteriaceae infections with ceftazidime\/avibactam: a retrospective study with molecular strain characterisation","volume":"49","author":"Krapp","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2023040308031609500_","first-page":"1173","article-title":"Ceftazidime-avibactam treatment in bacteremia caused by OXA-48 carbapenemase-producing Klebsiella pneumoniae","volume":"41","author":"Lima","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1007\/s40121-021-00506-7","article-title":"Clinical and microbiological outcomes of ceftazidime-avibactam treatment in adults with Gram-negative bacteremia: a subset analysis from the phase 3 clinical trial program","volume":"4","author":"Mazuski","year":"2021","journal-title":"Infect Dis Ther"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s15010-020-01539-9","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature","volume":"49","author":"Meschiari","year":"2021","journal-title":"Infection"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ijantimicag.2019.08.025","article-title":"Efficacy of ceftazidime\/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: a meta-analysis","volume":"54","author":"Onorato","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jgar.2018.07.010","article-title":"Evaluation of ceftazidime\/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa","volume":"15","author":"Rodr\u00edguez-N\u00fa\u00f1ez","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ijantimicag.2016.11.005","article-title":"Clinical experience with ceftazidime\/avibactam in patients with severe infections, including meningitis and lung abscesses, caused by extensively drug-resistant Pseudomonas aeruginosa","volume":"49","author":"Xipell","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ijantimicag.2018.01.016","article-title":"Clinical experience with ceftazidime\/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae","volume":"51","author":"Santevecchi","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e02097-16","DOI":"10.1128\/AAC.02097-16","article-title":"Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e00883-17","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1093\/jac\/dky295","article-title":"Effectiveness of ceftazidime\/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae","volume":"73","author":"Sousa","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e01964-16","DOI":"10.1128\/AAC.01964-16","article-title":"Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms","volume":"61","author":"Temkin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e02320-19","DOI":"10.1128\/AAC.02320-19","article-title":"Ceftazidime-avibactam to treat life-threatening infections by carbapenem-resistant pathogens in critically ill mechanically ventilated patients","volume":"64","author":"Tsolaki","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/cid\/ciy492","article-title":"Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae","volume":"68","author":"Tumbarello","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/cid\/ciab176","article-title":"Ceftazidime-avibactam use for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae infections: a retrospective observational multicenter study","volume":"73","author":"Tumbarello","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1002\/phar.1840","article-title":"Pharmacokinetics of ceftazidime-avibactam in two patients with KPC-producing Klebsiella pneumoniae bacteremia and renal impairment","volume":"36","author":"Veillette","year":"2016","journal-title":"Pharmacother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/antibiotics9020071","article-title":"Clinical experience with ceftazidime-avibactam for the treatment of infections due to multidrug-resistant Gram-negative bacteria other than carbapenem-resistant Enterobacterales","volume":"9","author":"Vena","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/cid\/ciw491","article-title":"Ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae bacteremia","volume":"63","author":"Wu","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"ofaa349","DOI":"10.1093\/ofid\/ofaa349","article-title":"Using therapeutic drug monitoring to treat KPC-producing Klebsiella pneumoniae central nervous system infection with ceftazidime\/avibactam","volume":"7","author":"Yasmin","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.2147\/IDR.S343505","article-title":"Efficacy of ceftazidime-avibactam in the treatment of carbapenem-resistant Klebsiella pneumoniae infection after kidney transplantation","volume":"14","author":"Zhang","year":"2021","journal-title":"Infect Drug Res"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s40121-022-00621-z","article-title":"Efficacy and pharmacodynamic target attainment for ceftazidime-avibactam off-label dose regimens in patients with continuous or intermittent venovenous hemodialysis: two case reports","volume":"11","author":"Zhang","year":"2022","journal-title":"Infect Dis Ther"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ijantimicag.2018.07.004","article-title":"Evaluation of the efficacy and safety of ceftazidime\/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis","volume":"52","author":"Zhong","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/j.1875-9114.1995.tb04366.x","article-title":"Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies","volume":"15","author":"Fish","year":"1995","journal-title":"Pharmacother"},{"issue":"Suppl 2","key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1086\/519256","article-title":"Optimizing drug exposure to minimize selection of antibiotic resistance","volume":"45","author":"Olofsson","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1128\/AAC.02177-15","article-title":"Suppression of emergence of resistance in pathogenic bacteria: keeping our powder dry, part 1","volume":"60","author":"Drusano","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1080\/14787210.2021.1924674","article-title":"Multidrug-resistant Klebsiella pneumoniae: mechanisms of resistance including updated data for novel \u03b2-lactam-\u03b2-lactamase inhibitor combinations","volume":"19","author":"Galani","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.eng.2020.11.004","article-title":"Epidemiology and mechanisms of ceftazidime\u2013avibactam resistance in Gram-negative bacteria","volume":"11","author":"Xu","year":"2021","journal-title":"Engineering"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e1571","DOI":"10.1002\/wsbm.1571","article-title":"Molecular mechanisms underlying bacterial resistance to ceftazidime\/avibactam","volume":"14","author":"Xiong","year":"2022","journal-title":"WIREs Mech Dis"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e0044722","DOI":"10.1128\/aac.00447-22","article-title":"Klebsiella pneumoniae carbapenemase variants resistant to ceftazidime-avibactam: an evolutionary overview","volume":"66","author":"Hobson","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1128\/AAC.01165-15","article-title":"First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate","volume":"59","author":"Humphries","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e00537-17","DOI":"10.1128\/AAC.00537-17","article-title":"Resistance to ceftazidime-avibactam in Klebsiella pneumoniae due to porin mutations and the increased expression of KPC-3","volume":"61","author":"Humphries","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e00989-17","DOI":"10.1128\/AAC.00989-17","article-title":"Resistance to ceftazidime-avibactam is due to transposition of KPC in a porin-deficient strain of Klebsiella pneumoniae with increased efflux activity","volume":"61","author":"Nelson","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1093\/jac\/dkz209","article-title":"Unravelling ceftazidime\/avibactam resistance of KPC-28, a KPC-2 variant lacking carbapenemase activity","volume":"74","author":"Oueslati","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1351\/pac198456050595","article-title":"Nomenclature and symbolism for amino acids and peptides","volume":"56","author":"International Union of Pure and Applied Chemistry and International Union of Biochemistry Joint Commission on Biochemical Nomenclature","year":"1984","journal-title":"Pure Appl Chem"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e00775-20","DOI":"10.1128\/mSphere.00775-20","article-title":"A ceftazidime-avibactam-resistant and carbapenem-susceptible Klebsiella pneumoniae strain harboring blaKPC-14 isolated in New York City","volume":"5","author":"Niu","year":"2020","journal-title":"mSphere"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.cmi.2020.03.013","article-title":"Emergence of ceftazidime\/avibactam resistance in KPC-8-producing Klebsiella pneumoniae in South America","volume":"26","author":"Garc\u00eda","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e01111-19","DOI":"10.1128\/AAC.01111-19","article-title":"Phenotypic, biochemical and genetic analysis of KPC-41, a KPC-3 variant conferring resistance to ceftazidime-avibactam and exhibiting reduced carbapenemase activity","volume":"63","author":"Mueller","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e00321-20","DOI":"10.1128\/AAC.00321-20","article-title":"KPC-50 confers resistance to ceftazidime-avibactam associated with reduced carbapenemase activity","volume":"64","author":"Poirel","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1128\/AAC.00163-15","article-title":"Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of \u03b2-lactamase-producing strains","volume":"59","author":"Castanheira","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.2147\/IDR.S219635","article-title":"CP-CRE\/non-CP-CRE stratification and CRE resistance mechanism determination help in better managing CRE bacteremia using ceftazidime\u2013avibactam and aztreonam\u2013avibactam","volume":"12","author":"Zou","year":"2019","journal-title":"Infect Drug Res"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.2147\/IDR.S257477","article-title":"Emergence of hypervirulent ceftazidime\/avibactam-resistant Klebsiella pneumoniae isolates in a Chinese tertiary hospital","volume":"13","author":"Li","year":"2020","journal-title":"Infect Drug Resist"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jgar.2020.04.023","article-title":"Genetic diversity and in vitro activity of ceftazidime\/avibactam and aztreonam\/avibactam against imipenem-resistant Enterobacteriaceae isolates in Southwest China: a single-centre study","volume":"22","author":"Wei","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"124.e1","DOI":"10.1016\/j.cmi.2019.08.020","article-title":"Emergence of ceftazidime\/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China","volume":"26","author":"Zhang","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e0206721","DOI":"10.1128\/aac.02067-21","article-title":"Selection of AmpC \u03b2-lactamase variants and metallo-\u03b2-lactamases leading to ceftolozane\/tazobactam and ceftazidime\/avibactam-resistance during treatment of MDR\/XDR Pseudomonas aeruginosa infections","volume":"66","author":"Ruedas-L\u00f3pez","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e00389-17","DOI":"10.1128\/AAC.00389-17","article-title":"Unusual Escherichia coli PBP 3 insertion sequence identified from a collection of carbapenem-resistant Enterobacteriaceae tested in vitro with a combination of ceftazidime-, ceftaroline-, or aztreonam-avibactam","volume":"61","author":"Zhang","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e02497-17","DOI":"10.1128\/AAC.02497-17","article-title":"Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections","volume":"62","author":"Shields","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e00408-18","DOI":"10.1128\/mSphere.00408-18","article-title":"Analyses of a ceftazidime-avibactam-resistant Citrobacter freundii isolate carrying blaKPC-2 reveals a heterogenous population and reversible genotype","volume":"3","author":"Castanheira","year":"2018","journal-title":"mSphere"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/jac\/dky082","article-title":"In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime\/avibactam treatment","volume":"73","author":"Gaibani","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e02101-17","DOI":"10.1128\/AAC.02101-17","article-title":"Successive emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in blaKPC-2-harboring Klebsiella pneumoniae sequence type 307 isolates","volume":"62","author":"Giddins","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1093\/jac\/dkz156","article-title":"KPC-31 expressed in a ceftazidime\/avibactam-resistant Klebsiella pneumoniae is associated with relevant detection issues","volume":"74","author":"Antonelli","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jgar.2019.11.007","article-title":"Use of carbapenems in the combined treatment of emerging ceftazidime\/avibactam-resistant and carbapenem-susceptible KPC-producing Klebsiella pneumoniae infections: report of a case and review of the literature","volume":"22","author":"Cano","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1093\/jac\/dkz330","article-title":"Emergence of ceftazidime\/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo","volume":"74","author":"G\u00f6ttig","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/jac\/dkz026","article-title":"Ceftazidime\/avibactam resistance associated with L169P mutation in the omega loop of KPC-2","volume":"74","author":"Hemarajata","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e01822-19","DOI":"10.1128\/mBio.01822-19","article-title":"Dynamic emergence of mismatch repair deficiency facilitates rapid evolution of ceftazidime-avibactam resistance in Pseudomonas aeruginosa acute infection","volume":"10","author":"Khil","year":"2019","journal-title":"mBio"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"1900256","DOI":"10.2807\/1560-7917.ES.2019.24.19.1900256","article-title":"Emergence of ceftazidime-avibactam-resistant Klebsiella pneumoniae during treatment, Finland, December 2018","volume":"24","author":"R\u00e4is\u00e4nen","year":"2019","journal-title":"Euro Surveill"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1093\/jac\/dkz201","article-title":"Identification of L169P mutation in the omega loop of KPC-3 after a short course of ceftazidime\/avibactam","volume":"74","author":"Venditti","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1093\/jac\/dkaa283","article-title":"Bloodstream infection by two subpopulations of Klebsiella pneumoniae ST1685 carrying KPC-33 or KPC-14 following ceftazidime\/avibactam treatment: considerations regarding acquired heteroresistance and choice of carbapenemase detection assay","volume":"75","author":"Bianco","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"105816","DOI":"10.1016\/j.ijantimicag.2019.09.020","article-title":"Genomic characterization of a Klebsiella pneumoniae ST1519 resistant to ceftazidime\/avibactam carrying a novel KPC variant (KPC-36)","volume":"55","author":"Gaibani","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10096-020-04000-9","article-title":"Emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in KPC-2-producing Klebsiella pneumoniae of sequence type 39 during treatment","volume":"40","author":"Galani","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3390\/ijms21031026","article-title":"Integrated genome-wide analysis of an isogenic pair of Pseudomonas aeruginosa clinical isolates with differential antimicrobial resistance to ceftolozane\/tazobactam, ceftazidime\/avibactam, and piperacillin\/tazobactam","volume":"21","author":"Huang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12866-021-02293-0","article-title":"Increased gene expression and copy number of mutated blaKPC lead to high-level ceftazidime\/avibactam resistance in Klebsiella pneumoniae","volume":"21","author":"Sun","year":"2021","journal-title":"BMC Microbiol"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.3390\/microorganisms9112356","article-title":"Ceftazidime\/avibactam-resistant Klebsiella pneumoniae subsp. pneumoniae isolates in a tertiary Italian hospital: identification of a new mutation of the carbapenemase type 3 (KPC-3) gene conferring ceftazidime\/avibactam resistance","volume":"9","author":"Fontana","year":"2021","journal-title":"Microorganisms"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijid.2021.10.028","article-title":"Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in a critically ill patient","volume":"113","author":"Gaibani","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.2147\/IDR.S306095","article-title":"Ceftazidime-avibactam resistance in Klebsiella pneumoniae sequence type 11 due to a mutation in plasmid-borne blaKPC-2 to blaKPC-33, in Henan, China","volume":"14","author":"Li","year":"2021","journal-title":"Infect Drug Resist"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"724272","DOI":"10.3389\/fmicb.2021.724272","article-title":"Emergence of a KPC variant conferring resistance to ceftazidime-avibactam in a widespread ST11 carbapenem-resistant Klebsiella pneumoniae clone in China","volume":"12","author":"Li","year":"2021","journal-title":"Front Microbiol"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jiac.2021.01.014","article-title":"Ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in KPC-producing Klebsiella pneumoniae infections: a case series","volume":"27","author":"van Asten","year":"2021","journal-title":"J Infect Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e0224521","DOI":"10.1128\/jcm.02245-21","article-title":"Impact of ceftazidime-avibactam treatment in the emergence of novel KPC variants in the ST307-Klebsiella pneumoniae high-risk clone and consequences for their routine detection","volume":"60","author":"Hern\u00e1ndez-Garc\u00eda","year":"2022","journal-title":"J Clin Microbiol"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jiph.2022.04.002","article-title":"Emergence of ceftazidime-avibactam resistance due to a novel blaKPC-2 mutation during treatment of carbapenem-resistant Klebsiella pneumoniae infections","volume":"15","author":"Liao","year":"2022","journal-title":"J Infect Publ Health"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1016\/S0140-6736(22)01011-X","article-title":"The changing face of Klebsiella pneumoniae carbapenemase: in-vivo mutation in patient with chest infection","volume":"399","author":"Shen","year":"2022","journal-title":"Lancet"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.3390\/antibiotics11111456","article-title":"Suboptimal concentrations of ceftazidime\/avibactam (CAZ-AVI) may select for CAZ-AVI resistance in extensively drug-resistant Pseudomonas aeruginosa: in vivo and in vitro evidence","volume":"11","author":"Lopez-Montesinos","year":"2022","journal-title":"Antibiotics"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e01841-19","DOI":"10.1128\/AAC.01841-19","article-title":"A standard numbering scheme for class C \u03b2-lactamases","volume":"64","author":"Mack","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e01637-19","DOI":"10.1128\/AAC.01637-19","article-title":"A 2.5-years within-patient evolution of a Pseudomonas aeruginosa with in vivo acquisition of ceftolozane-tazobactam and ceftazidime-avibactam resistance upon treatment","volume":"63","author":"Boulant","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"2000028","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000028","article-title":"Outbreak of KPC-2-producing Klebsiella pneumoniae endowed with ceftazidime-avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019","volume":"25","author":"Galani","year":"2020","journal-title":"Euro Surveill"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"1900766","DOI":"10.2807\/1560-7917.ES.2020.25.2.1900766","article-title":"Detection in two hospitals of transferable ceftazidime-avibactam resistance in Klebsiella pneumoniae due to a novel VEB \u03b2-lactamase variant with a Lys234Arg substitution, Greece, 2019","volume":"25","author":"Voulgari","year":"2020","journal-title":"Euro Surveill"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e00955-19","DOI":"10.1128\/AAC.00955-19","article-title":"Patient-to-patient transmission of Klebsiella pneumoniae carbapenemase variants with reduced ceftazidime-avibactam susceptibility","volume":"63","author":"Munoz-Price","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1128\/AAC.00678-15","article-title":"In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase","volume":"59","author":"Livermore","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e02534-16","DOI":"10.1128\/AAC.02534-16","article-title":"Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum \u03b2-lactamases","volume":"61","author":"Haidar","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1128\/AAC.00548-15","article-title":"Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum \u03b2-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae","volume":"59","author":"Shields","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e01117-17","DOI":"10.1128\/AAC.01117-17","article-title":"In vivo emergence of resistance to novel cephalosporin-\u03b2-lactamase inhibitor combinations through the duplication of amino acid D149 from OXA-2 \u03b2-lactamase (OXA-539) in sequence type 235 Pseudomonas aeruginosa","volume":"61","author":"Fraile-Ribot","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/jac\/dkaa396","article-title":"Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane\/tazobactam and ceftazidime\/avibactam during treatment of XDR Pseudomonas aeruginosa infections","volume":"76","author":"Arca-Su\u00e1rez","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e00084-21","DOI":"10.1128\/AAC.00084-21","article-title":"In vitro susceptibility of multidrug-resistant Pseudomonas aeruginosa following treatment-emergent resistance to ceftolozane-tazobactam","volume":"65","author":"Rubio","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/jac\/dkv004","article-title":"Selection and molecular characterization of ceftazidime\/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC","volume":"70","author":"Lahiri","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e0008921","DOI":"10.1128\/AAC.00089-21","article-title":"Emergence of resistance to novel cephalosporin-\u03b2-lactamase inhibitor combinations through the modification of the Pseudomonas aeruginosa MexCD-OprJ efflux pump","volume":"65","author":"Gomis-Font","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1073\/pnas.96.3.1152","article-title":"The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance","volume":"96","author":"Austin","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"20190363","DOI":"10.1098\/rsif.2019.0363","article-title":"Diffusion-driven enhancement of the antibiotic resistance selection window","volume":"16","author":"Fuentes-Hern\u00e1ndez","year":"2019","journal-title":"J R Soc Interface"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e0373322","DOI":"10.1128\/spectrum.03733-22","article-title":"Outbreak of Klebsiella pneumoniae ST11 resistant to ceftazidime-avibactam producing KPC-31 and the novel variant KPC-115 during COVID-19 pandemic in Argentina","volume":"10","author":"Nicola","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2023040308031609500_","first-page":"122","article-title":"Clinical and scientific importance of source control in abdominal infections: summary of a symposium","volume":"42","author":"Bohnen","year":"1999","journal-title":"Can J Surg"},{"key":"2023040308031609500_","first-page":"171","article-title":"Advances in source control in patients with sepsis and septic shock","volume":"18","author":"de Waele","year":"2018","journal-title":"ICU Management & Practice"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e02187-18","DOI":"10.1128\/AAC.02187-18","article-title":"Dose selection and validation for ceftazidime-avibactam in adults with complicated intra-abdominal infections, complicated urinary tract infections and nosocomial pneumonia","volume":"63","author":"Das","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","author":"European Commission"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ajic.2018.01.002","article-title":"Are antimicrobial stewardship programs effective strategies for preventing antibiotic resistance? A systematic review","volume":"46","author":"Bertollo","year":"2018","journal-title":"Am J Infect Control"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijantimicag.2015.02.027","article-title":"Ecological effect of ceftazidime\/avibactam on the normal human intestinal microbiota","volume":"46","author":"Rashid","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1128\/AAC.24.3.333","article-title":"Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora","volume":"24","author":"Kemmerich","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jgar.2018.11.014","article-title":"KPC-producing Klebsiella pneumoniae gut decolonisation following ceftazidime\/avibactam-based combination therapy: a retrospective observational study","volume":"17","author":"Bassetti","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.cmi.2017.08.026","article-title":"What is antimicrobial stewardship?","volume":"23","author":"Dyar","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0140-6736(86)90316-8","article-title":"Predicting gentamicin resistance from annual usage in hospital","volume":"2","author":"Goossens","year":"1986","journal-title":"Lancet"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"e02106-16","DOI":"10.1128\/AAC.02106-16","article-title":"Antimicrobial activities of ceftazidime-avibactam and comparator agents against clinical bacteria isolated from patients with cancer","volume":"61","author":"Hachem","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ijantimicag.2019.06.008","article-title":"Cost-effectiveness analysis of ceftazidime\/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections","volume":"54","author":"Kongnakorn","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2023040308031609500_","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13756-019-0652-x","article-title":"Cost-effectiveness analysis comparing ceftazidime\/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane\/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)","volume":"8","author":"Kongnakorn","year":"2019","journal-title":"Antimicrob Resist Infect Control"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/4\/871\/49727939\/dkad049.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/4\/871\/49727939\/dkad049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T18:51:14Z","timestamp":1701888674000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/4\/871\/7072206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":176,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,3,8]]},"published-print":{"date-parts":[[2023,4,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad049","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,4]]},"published":{"date-parts":[[2023,3,8]]}}}